Processes and Methods (incl. Screening)

Cholestatic liver diseases are a heterogeneous group of disorders resulting from genetic, metabolic and congenital defects, as well as DILI (drug-induced liver injury, a leading cause of attrition during drug development).

Current diagnostic techniques for DILI and cholestasis are based on the detection of serum markers and imaging methods such as computer tomography. However, these have a low resolution and only provide a limited understanding of the underlying disease etiology. Therapeutic ...

A precise and genetically encoded inhibitor for cell-type selective, inducible and reversible inhibition of protein synthesis

We offer a new family of cationic ligands, namely N-alkyl/aryl pyridiniophosphines. The ligands can be synthesized through a short, scalable, and highly modular route.

Evaluation of their electronic properties evidenced weak σ-donor and quite strong π-acceptor character when used as ancillary ligands.

Extremely sensitive, reliable and fast novel KDAC assay, which can be performed in a continuous format. This novel KDAC assay is based on Firefly luciferase harboring an acetylation on an essential active site lysine, incorporated by genetic code expansion. We furthermore offer a bacterial selection system for KDACs, which uses a reporter enzyme inactivated by lysine modifications at an essential active site residue, thereby linking deacetylase activity to a selectable output.

RNACasing: A novel and selective way of isolating and stabilizing RNA molecules, which enables processing, storing and shipping of RNA at room temperature.